AU2004280078B2 - Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin - Google Patents

Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin Download PDF

Info

Publication number
AU2004280078B2
AU2004280078B2 AU2004280078A AU2004280078A AU2004280078B2 AU 2004280078 B2 AU2004280078 B2 AU 2004280078B2 AU 2004280078 A AU2004280078 A AU 2004280078A AU 2004280078 A AU2004280078 A AU 2004280078A AU 2004280078 B2 AU2004280078 B2 AU 2004280078B2
Authority
AU
Australia
Prior art keywords
rapamycin
minitablets
composition according
coating
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004280078A
Other languages
English (en)
Other versions
AU2004280078A1 (en
Inventor
Dieter Becker
Carsten Burger
Gilles Feutren
Patrice Guitard
Andrea Kramer
Nicoletta Loggia
Christian-Peter Luftensteiner
Jorg Ogorka
Harald Ottinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004280078A1 publication Critical patent/AU2004280078A1/en
Application granted granted Critical
Publication of AU2004280078B2 publication Critical patent/AU2004280078B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004280078A 2003-10-03 2004-10-01 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin Ceased AU2004280078B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0323202.2 2003-10-03
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598.3 2003-10-08
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852.8 2003-12-23
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0405902.8 2004-03-16
GB0410714.0 2004-05-13
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356.1 2004-08-31
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds
PCT/EP2004/010998 WO2005034916A1 (en) 2003-10-03 2004-10-01 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin

Publications (2)

Publication Number Publication Date
AU2004280078A1 AU2004280078A1 (en) 2005-04-21
AU2004280078B2 true AU2004280078B2 (en) 2008-08-07

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004280078A Ceased AU2004280078B2 (en) 2003-10-03 2004-10-01 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin

Country Status (11)

Country Link
US (1) US20070036857A1 (enExample)
EP (1) EP1670437A1 (enExample)
JP (1) JP2007507458A (enExample)
AR (1) AR045957A1 (enExample)
AU (1) AU2004280078B2 (enExample)
BR (1) BRPI0414864A (enExample)
CA (1) CA2538099A1 (enExample)
MX (1) MXPA06003646A (enExample)
PE (1) PE20050755A1 (enExample)
TW (1) TW200520759A (enExample)
WO (1) WO2005034916A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
AU2007319825B2 (en) * 2006-11-14 2014-01-23 Ariad Pharmaceuticals, Inc. Oral formulations
RU2010109408A (ru) * 2007-08-13 2011-09-20 Панацея Биотек Лимитед (In) Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия
BRPI0909030A2 (pt) * 2008-03-05 2018-03-13 Panacea Biotec Ltd composições farmacêuticas de liberação modificada compreendendo micofenolato e processos para as mesmas.
WO2010150213A1 (en) * 2009-06-25 2010-12-29 Danisco A/S Protein
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2013050419A1 (en) * 2011-10-06 2013-04-11 Novartis Ag Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ，インコーポレイテッド ピロカルピンの医薬製剤
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
WO2018096402A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
CA3054817A1 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
AU2022422597A1 (en) * 2021-12-23 2024-07-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
US20250327799A1 (en) * 2022-05-16 2025-10-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551182A1 (en) * 1992-01-09 1993-07-14 American Home Products Corporation Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid
WO1995009626A1 (en) * 1993-10-01 1995-04-13 Syntex (U.S.A.) Inc. Mycophenolate mofetil high dose oral suspensions
US20020086059A1 (en) * 1996-10-14 2002-07-04 Roche Vitamins Inc. Process for the manufacture of a pulverous preparation
EP1221316A1 (en) * 1996-04-12 2002-07-10 Novartis AG Enteric-coated pharmaceutical compositions of mycophenolate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE474590T1 (de) * 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AU2003205586A1 (en) * 2002-01-10 2003-07-24 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
WO2004027027A2 (en) * 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551182A1 (en) * 1992-01-09 1993-07-14 American Home Products Corporation Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid
WO1995009626A1 (en) * 1993-10-01 1995-04-13 Syntex (U.S.A.) Inc. Mycophenolate mofetil high dose oral suspensions
EP1221316A1 (en) * 1996-04-12 2002-07-10 Novartis AG Enteric-coated pharmaceutical compositions of mycophenolate
US20020086059A1 (en) * 1996-10-14 2002-07-04 Roche Vitamins Inc. Process for the manufacture of a pulverous preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Merck Index, 2001, 13, 6352 *

Also Published As

Publication number Publication date
JP2007507458A (ja) 2007-03-29
AR045957A1 (es) 2005-11-16
EP1670437A1 (en) 2006-06-21
TW200520759A (en) 2005-07-01
BRPI0414864A (pt) 2006-11-28
WO2005034916A1 (en) 2005-04-21
CA2538099A1 (en) 2005-04-21
US20070036857A1 (en) 2007-02-15
AU2004280078A1 (en) 2005-04-21
MXPA06003646A (es) 2006-06-05
PE20050755A1 (es) 2005-11-28

Similar Documents

Publication Publication Date Title
AU2004280078B2 (en) Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin
AU2002338897B2 (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
US20080206322A1 (en) Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin
DK2210605T3 (en) Daily single dose doses of trospium.
AU2002338897A1 (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
AU2008288106B2 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
WO2009047799A1 (en) High dose solid unit oral pharmaceutical dosage form of mycophenolate sodium and process for making same
AU731693B2 (en) Drug formulation having controlled release of active compound
CA2578375A1 (en) Vaccine immunotherapy for immune suppressed patients
CN1863509A (zh) 包含麦考酚酸或麦考酚酸钠的多粒子药物组合物和与雷帕霉素的组合
HK1067861B (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired